PDLIM4: A Protein with Potential Therapeutic Effects (G8572)

Target Name: PDLIM4

NCBI ID: G8572

PDLIM4

PDLIM4: A Protein with Potential Therapeutic Effects

PDLIM4 (Proteasome-Driven LIM Domain Protein 4) is a protein that is expressed in a variety of tissues and cells throughout the body. It is a key player in the LIM (LIM) domain, a family of proteins that play a critical role in the regulation of protein homeostasis and degradation.

The PDLIM4 protein is characterized by its ability to interact with and regulate the activity of other proteins, particularly those involved in the ubiquitin-proteasome system (UPS). This system is responsible for the efficient degradation of damaged or unnecessary proteins, and is a key component of the immune system and the cytoskeleton.

PDLIM4 has been shown to play a critical role in the regulation of a variety of cellular processes, including cell division, apoptosis, and autophagy. It has also been shown to be involved in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a potential drug target, PDLIM4 is being targeted by researchers to investigate its potential therapeutic effects. Studies have shown that inhibiting the activity of PDLIM4 has the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to targeting PDLIM4 is to use small molecules that can inhibit its activity. Researchers have synthesized a variety of small molecules that have been shown to inhibit the activity of PDLIM4, and are currently in the process of testing their potential therapeutic effects.

Another approach to targeting PDLIM4 is to use antibodies that can specifically recognize and target the protein. Researchers have developed antibodies that are designed to recognize PDLIM4, and are currently testing their potential therapeutic effects in preclinical studies.

While the potential therapeutic effects of PDLIM4 are still being explored, it is clear that it is an important protein with significant implications for a variety of diseases. Further research is needed to fully understand its role and potential as a drug target.

Protein Name: PDZ And LIM Domain 4

Functions: Suppresses SRC activation by recognizing and binding to active SRC and facilitating PTPN13-mediated dephosphorylation of SRC 'Tyr-419' leading to its inactivation. Inactivated SRC dissociates from this protein allowing the initiation of a new SRC inactivation cycle (PubMed:19307596). Involved in reorganization of the actin cytoskeleton (PubMed:21636573). In nonmuscle cells, binds to ACTN1 (alpha-actinin-1), increases the affinity of ACTN1 to F-actin (filamentous actin), and promotes formation of actin stress fibers. Involved in regulation of the synaptic AMPA receptor transport in dendritic spines of hippocampal pyramidal neurons directing the receptors toward an insertion at the postsynaptic membrane. Links endosomal surface-internalized GRIA1-containing AMPA receptors to the alpha-actinin/actin cytoskeleton. Increases AMPA receptor-mediated excitatory postsynaptic currents in neurons (By similarity)

The "PDLIM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDLIM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets